{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzlmuq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzlmuq\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/4\\\/13\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/4\\\/13\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/4\\\/13\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/4\\\/13\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EIndicated for use in patients who were overweight (body mass index\u2005\u2265\u200527 kg\/m\u003Csup\u003E2\u003C\/sup\u003E with \u2265\u20051 comorbidities) or obese (body mass index\u2005\u2265\u200530 kg\/m\u003Csup\u003E2\u003C\/sup\u003E) without diabetes mellitus, liraglutide has proven safe and effective in the SCALE\u2013Obesity and Prediabetes trial. Combined with diet and exercise, liraglutide can improve weight and health-related quality-of-life factors.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eliraglutide\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eweight loss\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eweight management\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ESCALE trial\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EGLP-1\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ewaist circumference\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Efasting plasma glucose\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \n         \u003Cp id=\u0022p-2\u0022\u003EIn the phase 3, double-blind, randomized SCALE\u2013Obesity and Prediabetes trial [\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT01272219\u0026amp;atom=%2Fspmdc%2F15%2F4%2F13.atom\u0022\u003ENCT01272219\u003C\/a\u003E], significantly more obese and overweight adults without diabetes mellitus were weight loss responders when treated with liraglutide, 3 mg, rather than placebo. Weight loss responders also had improvements in glycemic control, cardiometabolic outcomes, and quality of life. The SCALE\u2013Obesity and Prediabetes trial was a subanalysis of the SCALE study, a large phase 3 clinical program investigating the safety and efficacy of liraglutide, 3 mg, for weight management in people with and without diabetes.\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EPatrick O\u2019Neil, PhD, Medical University of South Carolina, Charleston, South Carolina, USA, presented the results of the subanalysis. Overweight (body mass index [BMI]\u2005\u2265\u200527 kg\/m\u003Csup\u003E2\u003C\/sup\u003E with \u2265\u20051 comorbidities) or obese (BMI\u2005\u2265\u200530 kg\/m\u003Csup\u003E2\u003C\/sup\u003E) patients without diabetes mellitus were randomized to liraglutide, 3 mg (n\u2005=\u20052487), or placebo (n\u2005=\u20051244) as an adjunct to diet and exercise. Overall baseline characteristics included a mean age of 45 years, a body weight of 106 kg, and a BMI of 38 kg\/m\u003Csup\u003E2\u003C\/sup\u003E.\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EThe analysis compared key efficacy and safety outcomes of responders (\u2265\u20055% weight loss at week 56 from baseline) vs nonresponders (\u0026lt;\u20055% weight loss at week 56 from baseline). At week 56, significantly more individuals on liraglutide vs placebo were weight loss responders (63.2% vs 27.1%; \u003Cem\u003EP\u2005\u003C\/em\u003E\u0026lt;\u2005.0001). Mean weight loss for responders vs nonresponders on liraglutide was \u221211.7% vs \u22121.7%. In the placebo group, the respective figures were \u221210.0% vs +0.1%. Liraglutide was also associated with a greater reduction in waist circumference in responders vs nonresponders (\u201311.0 vs \u22123.3 cm). Respective figures in the placebo group were \u221210.0 vs \u22121.7 cm.\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EFasting plasma glucose was lower for responders in the liraglutide vs placebo group (\u20138.3 vs \u22122.8 mg\/dL). For nonresponders, the figures were \u22125.0 vs +1.1 mg\/dL. In liraglutide vs placebo responders, respective reductions in systolic blood pressure were \u22125.5 vs \u22123.4 mm Hg. Nonresponders in both groups had respective findings of \u22122.0 vs \u22120.8 mm Hg. Change in overall physical health scores on the SF-36 Health Survey Update questionnaire for liraglutide vs placebo responders was +4.3 vs +4.1; for nonresponders, the respective outcomes were +2.1 vs +1.3.\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003EThe most common adverse events (AEs) were gastrointestinal related. These were higher in liraglutide vs placebo responders (69.2% vs 44.4%, respectively) than in liraglutide and placebo nonresponders (67.2% vs 39.6%, respectively). Responders had lower rates of AEs leading to withdrawal (liraglutide, 4.5%; placebo, 0.9%). In nonresponders, the figures were 17% for liraglutide vs 4.8% for placebo.\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003ELiraglutide responders had greater improvements than nonresponders across a range of efficacy outcomes. Overall, weight loss\u2005\u2265\u20055% was achieved in a higher proportion of patients on liraglutide, 3 mg, with a stronger effect among responders. The rates of AEs were largely equivalent in responders and nonresponders.\u003C\/p\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EA mean weight loss of 11.7% was achieved by patients who were overweight or obese without diabetes and responded to liraglutide. The weight loss responders in both treatment groups also had improved glycemic, cardiometabolic, and health-related quality-of-life outcomes. The SCALE\u2013Obesity and Prediabetes trial showed that liraglutide is a safe and effective weight loss option in the study population.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/4\/13.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzlmuq\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}